A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs AZD 5718 (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms FLAVOUR
- Sponsors AstraZeneca
- 07 Jun 2018 Planned number of patients changed from 138 to 200.
- 10 May 2018 Planned number of patients changed from 200 to 138.
- 10 May 2018 Planned End Date changed from 25 Sep 2018 to 31 May 2019.